Craig Koniver

Overview

Craig Koniver is the physician guest in a Huberman Lab episode on peptides, hormone-related therapies, NAD, mitochondrial support, recovery, sleep, and performance medicine.

Current Profile

The source presents Koniver as a clinician whose practice uses supervised, frequently off-label or compounded interventions alongside lifestyle foundations. His contribution is primarily practitioner observation: he compares compounds, describes clinic protocols and patient responses, and argues for individualized assessment, trusted clinical guidance, legal access, and product-quality controls. Those observations can identify hypotheses and practical monitoring questions, but they do not substitute for controlled human evidence.

Key Characteristics

• Uses a performance-medicine frame aimed at health, function, recovery, and vitality rather than acute disease care alone.
• Describes extensive clinical use of peptides, NAD, methylene blue, supplements, and hormone-adjacent interventions.
• Emphasizes physician oversight, individualized dosing, medication and condition review, sourcing, sterility, and endotoxin control.
• Treats off-label prescribing and compounding as useful clinical tools while acknowledging regulatory and legal constraints.
• Places trust, positive framing, purpose, and foundational health behaviors alongside biomedical interventions.

Evidence

• Clinical practice - Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver records Koniver’s source-scoped protocols and observations across GLP-1 drugs, BPC-157, growth-hormone secretagogues, NAD, and methylene blue.
• Safety and access - Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver repeatedly distinguishes supervised compounding from research-use products and stresses patient assessment.
• Care philosophy - Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver describes his move away from short insurance-based visits toward longer performance-medicine relationships organized around energy, trust, and purpose.

Qualifications

This profile is bounded to one podcast summary and does not independently verify credentials, clinical outcomes, pharmacy quality, mechanisms, doses, or safety claims. The source body uses the surname “Conover,” but its metadata and title identify Craig Koniver; this page uses the metadata spelling. His patient reports and personal protocols remain clinical anecdotes rather than general treatment recommendations.

What Changed

• Created the entity to capture the episode’s practitioner perspective and its evidence boundary.
• Normalized the guest’s surname to Koniver while preserving the source’s spelling discrepancy as a qualification.

Relationships

• Andrew Huberman - interviewer who tests Koniver’s clinical claims against safety, sourcing, and evidence questions.
• Huberman Lab - show carrying the interview.
• Peptide Evidence Hierarchy - framework needed to classify the interventions Koniver discusses.
• Medical Risk Management - supervision boundary for experimental, compounded, off-label, and hormone-related care.
• NAD Therapy Evidence Boundary - evidence boundary for a prominent intervention in Koniver’s practice account.